These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22875583)

  • 1. Cavitary pulmonary metastases of pancreas cancer.
    Tamura T; Nakazawa K; Kagohashi K; Kurishima K; Satoh H
    J Gastrointest Cancer; 2013 Jun; 44(2):222-4. PubMed ID: 22875583
    [No Abstract]   [Full Text] [Related]  

  • 2. How fast can pancreatic cancer grow? A case of pancreatic carcinoma developed within 5 months after a negative examination to the advanced stage with multiple liver and bone metastases.
    Ko SB; Goto H
    Pancreas; 2011 Mar; 40(2):318-9. PubMed ID: 21311315
    [No Abstract]   [Full Text] [Related]  

  • 3. Gemcitabine-induced pulmonary toxicity in a patient with pancreatic cancer.
    Hiraya D; Kagohashi K; Sakamoto N; Kondo T; Satoh H
    JOP; 2010 Mar; 11(2):186-8. PubMed ID: 20208333
    [No Abstract]   [Full Text] [Related]  

  • 4. [A case of liver metastasis of pancreatic duct carcinoma successfully treated with gemcitabine].
    Tsujie M; Nakamori S; Nakazuru S; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):297-301. PubMed ID: 12610883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasound and microbubble enhanced treatment of inoperable pancreatic cancer.
    Park K
    J Control Release; 2016 Dec; 243():381. PubMed ID: 28024837
    [No Abstract]   [Full Text] [Related]  

  • 6. CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.
    Xu P; Yao J; He J; Zhao L; Wang X; Li Z; Qian J
    Oncotarget; 2016 Mar; 7(12):14831-40. PubMed ID: 26894380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
    Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
    Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.
    Bunt SK; Mohr AM; Bailey JM; Grandgenett PM; Hollingsworth MA
    Cancer Immunol Immunother; 2013 Feb; 62(2):225-36. PubMed ID: 22864396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo.
    Brockschmidt C; Hirner H; Huber N; Eismann T; Hillenbrand A; Giamas G; Radunsky B; Ammerpohl O; Bohm B; Henne-Bruns D; Kalthoff H; Leithäuser F; Trauzold A; Knippschild U
    Gut; 2008 Jun; 57(6):799-806. PubMed ID: 18203806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
    Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer. Breaching the cancer fortress.
    Olson P; Hanahan D
    Science; 2009 Jun; 324(5933):1400-1. PubMed ID: 19520948
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.
    Hingorani SR; Harris WP; Beck JT; Berdov BA; Wagner SA; Pshevlotsky EM; Tjulandin SA; Gladkov OA; Holcombe RF; Korn R; Raghunand N; Dychter S; Jiang P; Shepard HM; Devoe CE
    Clin Cancer Res; 2016 Jun; 22(12):2848-54. PubMed ID: 26813359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine resistance in pancreatic cancer: picking the key players.
    Kim MP; Gallick GE
    Clin Cancer Res; 2008 Mar; 14(5):1284-5. PubMed ID: 18316544
    [No Abstract]   [Full Text] [Related]  

  • 14. Vascular enhancement pattern of mass in computed tomography may predict chemo-responsiveness in advanced pancreatic cancer.
    Kim SI; Shin JY; Park JS; Jeong S; Jeon YS; Choi MH; Choi HJ; Moon JH; Hwang JC; Yang MJ; Yoo BM; Kim JH; Lee HW; Kwon CI; Lee DH
    Pancreatology; 2017; 17(1):103-108. PubMed ID: 27780664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEGPH20 for metastatic pancreatic ductal adenocarcinoma.
    Gourd E
    Lancet Oncol; 2018 Feb; 19(2):e81. PubMed ID: 29276021
    [No Abstract]   [Full Text] [Related]  

  • 17. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
    Beatty GL; Chiorean EG; Fishman MP; Saboury B; Teitelbaum UR; Sun W; Huhn RD; Song W; Li D; Sharp LL; Torigian DA; O'Dwyer PJ; Vonderheide RH
    Science; 2011 Mar; 331(6024):1612-6. PubMed ID: 21436454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Binenbaum Y; Na'ara S; Gil Z
    Drug Resist Updat; 2015 Nov; 23():55-68. PubMed ID: 26690340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
    Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
    Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
    Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
    Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.